PeptideDB

Vapreotide acetate

CAS No.: 849479-74-9

Vapreotide acetate (BMY-41606 acetate) is an antagonist of the neurokinin-1 (NK1) receptor (IC50: 330 nM).
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description Vapreotide acetate (BMY-41606 acetate) is an antagonist of the neurokinin-1 (NK1) receptor (IC50: 330 nM).
In vitro 按剂量依赖性,Vapreotide减弱了SP(物质P)引发的HEK293-NK1R和U373MG细胞系内的细胞内钙增加和NF-κB激活。Vapreotide抑制SP诱导的IL-8和MCP-1的产生。体外试验中,Vapreotide能够抑制人MDM的HIV-1感染,此作用通过SP预处理可逆转[1]。Vapreotide在低至10(-12)-10(-14) M的浓度下显著抑制人垂体腺瘤细胞释放GH、PRL和/或α亚单位。Vapreotide抑制GH释放(IC50:0.1 pM)[2]。Vapreotide对SSTR2、-3和-5表现出中等至高亲和力,IC50分别为0.17、0.1和21 nM,而对SSTR1和-4的亲和力较低,IC50分别为200和620 nM。RC-160抑制表达SSTR2和SSTR5的CHO细胞的血清诱导增殖(EC50s:53 和 150 pM)[3]。
In vivo 食管胃静脉曲张破裂出血是肝硬化门脉高压的严重并发症。急性给药实验中,Vapreotide降低大鼠侧支循环的血流量,而长期给药则减缓了其发展[4]。RC-160通过皮下注射,每日每只动物100 μg剂量,可减少肿瘤体积和重量约40%。若在肿瘤发展早期开始治疗,Vapreotide能够抑制雄激素非依赖性前列腺癌的增长[5]。
Target activity NK1:330 nM
Synonyms RC-160 acetate, 醋酸伐普肽, BMY-41606 acetate
molecular weight 1191.42
Molecular formula C59H74N12O11S2
CAS 849479-74-9
Storage keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility H2O: 14 mg/mL (11.75 mM), Sonication is recommended.
References 1. Spitsin S, et al. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor. Neuroimmunomodulation. 2013;20(5):247-55. 2. Hofland LJ, et al. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on theinhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology. 1994 Jan;134(1):301-6. 3. Buscail L, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4. 4. Veal N, et al. Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis. Dig Dis Sci. 2003 Jan;48(1):154-61. 5. Pinski J, et al. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.